Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if involved), nor does it represent the platform's position.Authorization is required for any article reprints.
On June 8, Oricell Therapeutics Holdings Limited (hereinafter referred to as “Qrigincell Therapeutics,” “Oricell,” or the “Company”), a global leader in innovative tumor immunotherapy, announced that its independently developedTargeted GPC3 Chimeric Antigen Receptor Autologous T Cell Injection (Code: Ori-C101)Approved by the National Medical Products Administration (NMPA) of China to enter Phase II confirmatory clinical trials for GPC3-positive, late-line hepatocellular carcinoma (HCC).This study is a prospective, randomized controlled, open-label, nationwide multicenter registry clinical trial aimed at evaluating the efficacy and safety of Ori-C101 in patients with advanced hepatocellular carcinoma who have previously failed second-line or later treatments. Information indicates that C101 has the potential to become the world's first CAR-T drug for treating liver cancer.At the recently concluded 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the Phase I clinical study (BEACON) results of Ori-C101 were presented as an oral report, revealing exciting data that has attracted significant attention from the industry. The study enrolled patients with advanced liver cancer who had failed at least second-line treatment (all had received TKI + ICI therapy). Among them, the objective response rate (ORR) in the overall population reached 50%; specifically, the ORR in the recommended Phase II dose (RP2D) group was 66.7%, while the ORR in the highest dose group (DL4) reached 100%.Ori‑C101An autologous CAR-T cell therapy targeting GPC3, developed by Qrigincell Therapeutics, with its core indication being the treatment of advanced hepatocellular carcinoma (HCC).Leveraging the proprietary Ori®Ab (AI-powered antibody discovery and engineering platform) and Ori®Armoring (structure-enhanced cell platform), it enables efficient identification and killing of GPC3-positive tumor cells.
References:
Public Information
Scan the QR code to join the groupMaster CAR-T therapy, stem cell therapy, geneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Therapeutics
